Búsqueda | Biblioteca Virtual en Salud

1.

Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE.

Heller, Simon; Lingvay, Ildiko; Marso, Steven P; Philis-Tsimikas, Athena; Pieber, Thomas R; Poulter, Neil R; Pratley, Richard E; Hachmann-Nielsen, Elise; Kvist, Kajsa; Lange, Martin; Moses, Alan C; Trock Andresen, Marie; Buse, John B.

Diabetes Obes Metab ; 22(12): 2248-2256, 2020 12.

Artículo en Inglés | MEDLINE | ID: mdl-32996693

2.

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.

Heller, Simon; Lingvay, Ildiko; Marso, Steven P; Philis-Tsimikas, Athena; Pieber, Thomas R; Poulter, Neil R; Pratley, Richard E; Hachmann-Nielsen, Elise; Kvist, Kajsa; Lange, Martin; Moses, Alan C; Andresen, Marie Trock; Buse, John B.

Diabetes Obes Metab ; 22(12): 2241-2247, 2020 12.

Artículo en Inglés | MEDLINE | ID: mdl-32250536

3.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley, Richard E; Emerson, Scott S; Franek, Edward; Gilbert, Matthew P; Marso, Steven P; McGuire, Darren K; Pieber, Thomas R; Zinman, Bernard; Hansen, Charlotte T; Hansen, Melissa V; Mark, Thomas; Moses, Alan C; Buse, John B.

Diabetes Obes Metab ; 21(7): 1625-1633, 2019 07.

Artículo en Inglés | MEDLINE | ID: mdl-30850995

4.

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen, Kirstine; Emerson, Scott S; McGuire, Darren K; Pieber, Thomas R; Poulter, Neil R; Pratley, Richard E; Zinman, Bernard; Ranthe, Mattis F; Grøn, Randi; Lange, Martin; Moses, Alan C; Örsy, Petra; Buse, John B.

Diabetes Obes Metab ; 21(6): 1437-1444, 2019 06.

Artículo en Inglés | MEDLINE | ID: mdl-30793465

5.

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

Marso, Steven P; Poulter, Neil R; Nissen, Steven E; Nauck, Michael A; Zinman, Bernard; Daniels, Gilbert H; Pocock, Stuart; Steinberg, William M; Bergenstal, Richard M; Mann, Johannes F E; Ravn, Lasse Steen; Frandsen, Kirstine Brown; Moses, Alan C; Buse, John B.

Am Heart J ; 166(5): 823-30.e5, 2013 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-24176437

6.

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.

Heller, Simon R; Buse, John B; Ratner, Robert; Seaquist, Elizabeth; Bardtrum, Lars; Hansen, Charlotte Thim; Tutkunkardas, Deniz; Moses, Alan C.

Diabetes Care ; 43(2): 398-404, 2020 02.

Artículo en Inglés | MEDLINE | ID: mdl-31658975

7.

Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).

Theilgaard, Hanne; Mollerup, Inger; Helmark, Ida Carøe; Endahl, Lars; Hoskin, Shawn; Hvelplund, Anders; Amby, Lene Klixbüll; Moses, Alan C.

Ther Innov Regul Sci ; 53(2): 279-286, 2019 03.

Artículo en Inglés | MEDLINE | ID: mdl-29793353

8.

Effectiveness of primary care-relevant treatments for obesity in adults.

Moses, Alan C; Handelsman, Yehuda; Einhorn, Daniel.

Ann Intern Med ; 156(3): 248-9; author reply 249, 2012 Feb 07.

Artículo en Inglés | MEDLINE | ID: mdl-22312148

9.

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

Gavrila, Alina; Hsu, William; Tsiodras, Sotirios; Doweiko, John; Gautam, Shiva; Martin, Lizabeth; Moses, Alan C; Karchmer, Adolf W; Mantzoros, Christos S.

Clin Infect Dis ; 40(5): 745-9, 2005 Mar 01.

Artículo en Inglés | MEDLINE | ID: mdl-15714423

10.

Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?

Moses, Alan C.

Endocr Dev ; 9: 121-134, 2005.

Artículo en Inglés | MEDLINE | ID: mdl-15879694

11.

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Steinberg, William M; Nauck, Michael A; Zinman, Bernard; Daniels, Gilbert H; Bergenstal, Richard M; Mann, Johannes F E; Steen Ravn, Lasse; Moses, Alan C; Stockner, Mette; Baeres, Florian M M; Marso, Steven P; Buse, John B.

Pancreas ; 43(8): 1223-31, 2014 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-25275271

12.

Diabetes prevention: perspectives and actions of one company.

Moses, Alan C; Mawby, Michael; Phillips, Anne M.

Am J Prev Med ; 44(4 Suppl 4): S333-8, 2013 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-23498295

13.

Commentary: will it take Harry Potter to solve diabetes? Divining the future of diabetes care.

Moses, Alan C.

J Periodontol ; 78(11): 2077-80, 2007 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-17970673

14.

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.

Hegedüs, Laszlo; Moses, Alan C; Zdravkovic, Milan; Le Thi, Tu; Daniels, Gilbert H.

J Clin Endocrinol Metab ; 96(3): 853-60, 2011 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-21209033

15.

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Bjerre Knudsen, Lotte; Madsen, Lars Wichmann; Andersen, Søren; Almholt, Kasper; de Boer, Anne S; Drucker, Daniel J; Gotfredsen, Carsten; Egerod, Frederikke Lihme; Hegelund, Anne Charlotte; Jacobsen, Helene; Jacobsen, Søren Dyring; Moses, Alan C; Mølck, Anne-Marie; Nielsen, Henriette S; Nowak, Jette; Solberg, Helene; Thi, Tu D L; Zdravkovic, Milan; Moerch, Ulrik.

Endocrinology ; 151(4): 1473-86, 2010 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-20203154

16.

Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.

Knudsen, Lotte Bjerre; Nyborg, Niels C Berg; Svendsen, Claus Bo; Vrang, Niels; Moses, Alan C.

Diabetes Care ; 36(12): e213, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24265382

17.

Comment on "The broken pen penalty" (Lakshmanadoss et al.).

Moses, Alan C.

Diabetes Technol Ther ; 12(11): 929-30, 2010 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-20879961

18.

Response to Swinnen et al.

Moses, Alan C; Koenen, Christoph.

Diabetes Technol Ther ; 12(6): 503-5, 2010 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-20470235

19.

Insulin-Like Growth Factor I in Human Thyroid Tissue: Specific Localization by Immunohistochemistry and In Situ Hybridization.

Maciel, Rui M. B.; Kimura, Edna T.; Takahaski, Mirian H.; Lopes, Maria-Honorina C.; Mesquita, Maria-Isabel S.; Moses, Alan C.; Alberti, Vania N..

Endocr Pathol ; 6(3): 207-215, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-12114741

20.

Joslin diabetes mellitus / Joslins daibetes mellitus

Kahn, C. Ronald; Weir, Gordon C; King, George L; Jacobson, Alan M; Moses, Alan C; Smith, Robert J.

Porto Alegre; Artmed Editora; 14 ed; 2009. 341 p. graf, ilus, tab.

Monografía en Portugués | SMS-SP, AHM-Acervo, TATUAPE-Acervo | ID: sms-2563

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE.

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.

Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).

Effectiveness of primary care-relevant treatments for obesity in adults.

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Diabetes prevention: perspectives and actions of one company.

Commentary: will it take Harry Potter to solve diabetes? Divining the future of diabetes care.

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.

Comment on "The broken pen penalty" (Lakshmanadoss et al.).

Response to Swinnen et al.

Insulin-Like Growth Factor I in Human Thyroid Tissue: Specific Localization by Immunohistochemistry and In Situ Hybridization.

Joslin diabetes mellitus / Joslins daibetes mellitus